Antibody-drug Conjugate Information
General Information of This Antibody-drug Conjugate (ADC)
| ADC ID |
DRG0KYBXW
|
|||||
|---|---|---|---|---|---|---|
| ADC Name |
ZW191
|
|||||
| Synonyms |
ZW191
Click to Show/Hide
|
|||||
| Organization |
Zymeworks (Originator)
|
|||||
| Drug Status |
Phase 1
|
|||||
| Drug-to-Antibody Ratio |
8
|
|||||
| Structure |
|
|||||
| Antibody Name |
Anti-FOLR1 IgG1 mAb
|
Antibody Info | ||||
| Antigen Name |
Folate receptor alpha (FOLR1)
|
Antigen Info | ||||
| Payload Name |
ZD06519
|
Payload Info | ||||
| Therapeutic Target |
DNA topoisomerase 1 (TOP1)
|
Target Info | ||||
| Linker Name |
Mc-Gly-Gly-Phe-Gly-AM
|
Linker Info | ||||
| Conjugate Type |
Random Cysteines
|
|||||
The indication landscape of This ADC(2027 Update)
The clinical trial pipeline of This ADC(2027 Update)
| Indication | Phase 1 | Phase 1/2 | Phase 2 | Phase 2/3 | Phase 3 | New Drug Application | Approved | ||
|---|---|---|---|---|---|---|---|---|---|
| Endometrial cancer |
1 Trials
|
||||||||
| Lung cancer |
1 Trials
|
||||||||
| Ovarian cancer |
1 Trials
|
||||||||
| Unspecific solid tumor |
1 Trials
|
General Information of The Activity Data Related to This ADC
Identified from the Human Clinical Data
Full List of Activity Data of This Antibody-drug Conjugate
Identified from the Human Clinical Data
| Experiment 1 Reporting the Activity Date of This ADC | [1] | ||||
| Patients Enrolled |
Eligibility: Locally advanced/unresectable or metastatic cancer (measurable per RECIST v1.1), ECOG 0-1, LVEF ≥50%, and adequate organ function. Exclusions: active malignancies requiring treatment, prior TOPO1i ADC therapy, uncontrolled organ dysfunction (renal/liver/pancreatic), or severe active infections (including SARS-CoV-2) needing systemic therapy.
Click to Show/Hide
|
||||
| Administration Dosage |
.
|
||||
| Related Clinical Trial | |||||
| NCT Number | NCT06555744 | Clinical Status | PHASE1 | ||
| Clinical Description | A Phase 1, Open-label, Multicenter Study to Assess the Safety, Tolerability, Pharmacokinetics, and Preliminary Anti-tumor Activity of Ascending Doses of a Folate Receptor Alpha Antibody Drug Conjugate, ZW191, in Participants With Advanced Solid Tumors | ||||
| Primary Endpoint |
Primary safety outcomes (Parts 1-2) include dose-limiting toxicities (DLTs) evaluated within 3 weeks, treatment-related adverse events (AEs), special interest AEs (AESIs), serious AEs (SAEs), and Grade 3+ lab abnormalities per CTCAE v5.0. Key efficacy measures (Part 2) focus on confirmed objective response rate (ORR) by RECIST v1.1 (CR/PR).
|
||||
| Other Endpoint |
Secondary endpoints (Parts 1-2) assess clinical benefit rate (CR/PR/non-CR non-PD/SD lasting ≥180 days), duration of response (DOR), disease control rate (DCR), progression-free survival (PFS), and best overall response (BOR). Pharmacokinetics (serum concentrations & ADA development) will be monitored throughout the study.
|
||||